Damora Therapeutics, Inc. Ordinary Shares DMRA
$24.53
-0.89%
at last close
Analyst Consensus
- Consensus Rating
- Buy (5 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $44.20
- Implied Upside
- +80.2%
- Price Target Range
- $40.00 – $50.00
- Analysts (12 mo)
- 5
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-07-30 | WedbushDavid Nierengarten |
Maintains | Outperform | $35 → $40 |
| 2026-07-27 | JefferiesAkash Tewari |
Initiates coverage on | Buy | $50 |
| 2026-07-21 | HC Wainwright & Co.Mitchell S. Kapoor |
Reiterates | Buy | $45 |
| 2026-06-12 | WedbushDavid Nierengarten |
Reiterates | Outperform | $35 |
| 2026-06-11 | HC Wainwright & Co.Mitchell S. Kapoor |
Initiates coverage on | Buy | $45 |
| 2026-05-28 | WedbushDavid Nierengarten |
Initiates coverage on | Outperform | $35 |
| 2026-04-24 | RBC CapitalBrian Abrahams |
Initiates coverage on | Outperform | $40 |
| 2026-03-25 | Evercore ISI GroupGavin Clark-Gartner |
Initiates coverage on | Outperform | $46 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $24.53
- Market Cap
- $1.51 billion
- 52-Week Range
- $16.50 – $34.89
- Average Volume
- 437K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.